Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Fineline Cube Jan 13, 2026
Company Drug

CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients

Fineline Cube Jan 13, 2026
Company Deals

Eli Lilly Partners with Genetic Leap for RNA-Targeted AI Drug Discovery

Fineline Cube Sep 6, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has...

Company

Euroapi to Downsize API Production, Citing Asian Competition and Market Stagnation

Fineline Cube Sep 6, 2024

Euroapi (EPA: EAPI), a French company and a spinoff from Sanofi established in 2022, has...

Company Deals

Rigel Pharmaceuticals Strikes Deal with Kissei for Development and Commercialization of Rezlidhia in East Asia

Fineline Cube Sep 6, 2024

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), a biopharmaceutical company based in the U.S., has entered into...

Company Drug

Sinocelltech’s Herpes Zoster Vaccine SCTV04C Clears NMPA for Clinical Trial

Fineline Cube Sep 6, 2024

Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has received approval from...

Company Deals

Voyager Therapeutics Secures Licensing Deal with Novartis for Gene Therapy Capsid

Fineline Cube Sep 6, 2024

Voyager Therapeutics Inc. (NASDAQ: VYGR), a U.S.-based biotechnology company, has announced a licensing agreement with...

Company Medical Device

Fujirebio’s HBsAg Detection Kit Receives NMPA Approval, Enhances Early Diagnosis Capabilities

Fineline Cube Sep 6, 2024

Fujirebio Inc., a leading diagnostic company based in Japan, has received approval from China’s National...

Company Drug

Jiangsu Kanion Pharmaceutical Gets NMPA Go-Ahead for Psoriasis Drug Clinical Trial

Fineline Cube Sep 6, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a prominent pharmaceutical company based in China, has...

Company Medical Device

Genesis MedTech Secures NMPA Approval for Innovative Surgical Energy Products

Fineline Cube Sep 6, 2024

Genesis MedTech, a leading medical device company headquartered in Singapore, has secured marketing approvals from...

Company Medical Device

True Health’s Advanced Microwave Ablation System Gains NMPA Nod for Liver Tumor Treatment

Fineline Cube Sep 6, 2024

True Health (Guangdong Hengqin) Medical Technology Co., Ltd has received marketing approval from China’s National...

Company Medical Device

Venus Medtech Initiates Global Study with Venus Vitae TAVR System Implantations

Fineline Cube Sep 6, 2024

Venus Medtech (Hangzhou) Inc., listed on the Hong Kong Stock Exchange as HKG: 2500, has...

Policy / Regulatory

China’s Hainan Free Trade Port Implements ‘Zero Tax’ on Medical Imports for Designated Entities

Fineline Cube Sep 6, 2024

In a joint effort to bolster healthcare services, China’s Ministry of Finance, National Health Commission...

Company Drug

Viatris Launches First-of-Its-Kind Nasal Spray Dymista in China for Allergic Rhinitis

Fineline Cube Sep 6, 2024

Viatris Inc. (NASDAQ: VTRS), a leading global pharmaceutical company based in the U.S., has announced...

Company Medical Device

Sansure Biotech Wins NMPA Nod for ALDH2 Gene Polymorphism Detection Kit

Fineline Cube Sep 5, 2024

Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced...

Company Drug

Novo Nordisk Advances in China with Submission of Sogroya for Adult Growth Hormone Deficiency

Fineline Cube Sep 5, 2024

Denmark’s pharmaceutical heavyweight, Novo Nordisk (NYSE: NVO), has reached a significant milestone with the National...

Company

AstraZeneca China Restructures Biopharma Unit to Boost Chronic Disease Management

Fineline Cube Sep 5, 2024

AstraZeneca (NASDAQ: AZN)’s Chinese subsidiary has announced a strategic restructuring of its China biopharmaceutical business...

Company Drug

Kelun-Biotech’s ADC for Cancer Gets NMPA Review, Expands MSD Collaboration

Fineline Cube Sep 5, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has achieved a regulatory milestone with its clinical...

Company Deals R&D

Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments

Fineline Cube Sep 5, 2024

Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked...

Company Drug

Roche’s Columvi for Relapsed DLBCL Gets Review Nod from China’s CDE for New Indication

Fineline Cube Sep 5, 2024

The Center for Drug Evaluation (CDE) in China has accepted for review an additional indication...

Company Drug

Jiangsu Hengrui’s Ivarmacitinib for Adult Alopecia Areata Accepted for Review by China’s CDE

Fineline Cube Sep 5, 2024

The Center for Drug Evaluation (CDE) has given the green light for the review of...

Policy / Regulatory R&D

US Allows Science and Technology Agreement with China to Expire, Pointing to Deepening R&D Competition

Fineline Cube Sep 5, 2024

The US-China Science and Technology Agreement (STA), a pivotal accord initially inked in 1979 by...

Posts pagination

1 … 244 245 246 … 609

Recent updates

  • Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes
  • CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients
  • Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk
  • ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform
  • Hengrui’s SHR‑1826 ADC Earns Breakthrough Therapy Designation for c‑Met Overexpressed NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Company Drug

CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients

Company Medical Device

Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk

Company Drug

ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.